Biotechnology
Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange
YICHANG, China, Feb. 6, 2026 /PRNewswire/ -- Angel Yeast Group
2026-02-07 09:31
3234
Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approv...
2026-02-06 17:00
2418
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...
2026-02-06 13:10
2172
World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rong...
2026-02-06 07:30
2612
Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combi...
2026-02-06 01:04
3038
Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors
Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts. CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnolog...
2026-02-05 21:00
2516
Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.
SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurolog...
2026-02-05 11:48
3421
Finally, a Natural Alternative to Acacia Gum in Beverages
RIVER FALLS, Wis., Feb. 5, 2026 /PRNewswire/ -- Fiberstar, Inc., the leader of
innovative citrus fibers launched an all-natural alternative to acacia gum –
Citri-Fi® Pro
2026-02-04 23:19
1965
NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...
2026-02-04 21:56
4132
Telix Full Year Results 2025 Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST). An invest...
2026-02-04 05:38
3293
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an inn...
2026-02-03 11:22
3329
SBC Medical-Supported Medical Corporation Nasukai Forms Strategic Alliance with Daibi Medical Aesthetics
Alliance to Enhance Shonan Beauty Clinic Brand Recognition in China and Support Growth in Inbound Medical Demand to Japan IRVINE, Calif., Feb. 2, 2026 /PRNewswire/ -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a global provider of comprehensive consul...
2026-02-02 10:00
4329
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ...
2026-01-30 19:54
5224
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...
2026-01-29 20:00
3298
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...
2026-01-29 19:00
3987
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...
2026-01-29 10:10
4371
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...
2026-01-29 07:43
3188
REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...
2026-01-28 22:00
4365
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
3411
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...
2026-01-27 21:00
4010
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 323 media titles]
2026-02-02 10:00
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 315 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 311 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 305 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 288 media titles]
2026-02-01 19:35Most Read
XPENG Announces Vehicle Delivery Results for January 2026
2026-02-01 17:00
5928
DaVinci Gourmet Named Title Sponsor of The World's 100 Best Coffee Shops 2026, to Be Unveiled in Madrid
2026-02-06 21:28
5538
Futu Holdings Wins Five CME Awards, Cementing Industry Leadership in Futures and Options
2026-02-02 10:36
5430
